N‐acetylcysteine in the treatment of craving in substance use disorders: Systematic review and meta‐analysis
- 12 September 2017
- journal article
- review article
- Published by Wiley in The American Journal on Addictions
- Vol. 26 (7) , 660-666
Abstract
Background and Objectives: Recent neurobiological evidences along with clinical observations justify the use of N‐acetylcysteine (NAC) as a medication for craving. The objective of our study was to assess the evidence of efficacy of NAC for craving in substance use disorders in randomized clinical trials (RCTs).Methods: Systematic review of the RCTs literature (PROSPERO number 56698) until February, 2017, using MEDLINE, Cochrane Library and clinicaltrials.gov. We included seven RCTs (n = 245); most with small‐to‐moderate sample sizes. The main outcome was the Hedges’ g for continuous scores in a random‐effects model. Heterogeneity was evaluated with the I2 and the χ2 test. Publication bias was evaluated using the Begg's funnel plot and the Egger's test. Meta‐regression was performed using the random‐effects model.Results: Comparing NAC versus placebo, NAC was significantly superior for craving symptoms (Hedges’ g = 0.94; 95%CI 0.55–1.33). The funnel plot showed the risk of publication bias was low and between‐study heterogeneity was not significant (I2 = 44.4%, p = 0.07 for the χ2 test). A subgroup analysis performed using meta‐regression showed no particular influence.Discussion and Conclusions: NAC was superior to placebo for craving reduction in SUDs. The relatively small number of trials and their heterogeneous methodology were possible limitations; however, these positive thrilling results stimulate further studies for clarifying the potential impact of NAC for craving symptoms in SUDs.Scientific Significance: The safety profile of NAC and favorable tolerability, in addition to being an over‐the‐counter medication, presents with an interesting potential clinical use for craving in SUDs.Scientific Significance: The safety profile of NAC and its favorable tolerability, in addition to being anover‐the‐counter medication, presents with an interesting potential clinical use for craving in SUDs. (Am J Addict 2017;26:660–666)Keywords
Funding Information
- National Health and Medical Research Council (1059660)
This publication has 36 references indexed in Scilit:
- Glutamate transporter GLT‐1 mediates N‐acetylcysteine inhibition of cocaine reinstatementAddiction Biology, 2014
- Potential Role of N-Acetylcysteine in the Management of Substance Use DisordersCNS Drugs, 2014
- The Story of Glutamate in Drug Addiction and ofN-Acetylcysteine as a Potential PharmacotherapyJAMA Psychiatry, 2013
- Translational and reverse translational research on the role of stress in drug craving and relapsePsychopharmacology, 2011
- N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of actionJournal of Psychiatry and Neuroscience, 2011
- Self-reports of interoceptive responses during stress and drug cue-related experiences in cocaine- and alcohol-dependent individuals.Experimental and Clinical Psychopharmacology, 2010
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and ElaborationPLOS Medicine, 2009
- Stress-Induced Cocaine Craving and Hypothalamic-Pituitary-Adrenal Responses Are Predictive of Cocaine Relapse OutcomesArchives of General Psychiatry, 2006
- Neural activity associated with stress-induced cocaine craving: a functional magnetic resonance imaging studyPsychopharmacology, 2005
- Neurobiologic Processes in Drug Reward and AddictionHarvard Review of Psychiatry, 2004